Health ❯ Healthcare ❯ Clinical Trials ❯ Drug Development

Eli Lilly

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

Unusually large, sustained reductions reported by Lilly could reshape obesity treatment if regulators approve the drug this year.

FDA Clears Eli Lilly’s Foundayo Oral GLP-1 for Weight Loss, With U.S. Launch Set for April 6

Novo’s CagriSema Falls Short of Lilly’s Tirzepatide in 84-Week Head‑to‑Head Trial

Lilly Files Orforglipron Obesity Pill With FDA After Trial Shows Weight-Loss Maintenance

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain

Lilly’s Orforglipron Pill Hits Phase 3 Goals and Outperforms Oral Semaglutide in Diabetes Study